Cellular innate immunity and restriction of viral infection: Implications for lentiviral gene therapy in human hematopoietic cells

Human Gene Therapy

Volumn 26, Issue 4, 2015, Pages 201-209

  Kajaste Rudnitski, Anna ^a,b   Naldini, Luigi ^a,b,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HOST FACTOR; LENTIVIRUS VECTOR; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR;

CELLULAR IMMUNITY; EX VIVO GENE TRANSFER; HEMATOPOIETIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; VESICULOVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS INFECTION; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LENTIVIRINAE; PHYSIOLOGY;

ANIMALS; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; LENTIVIRUS; TRANSDUCTION, GENETIC; VIRUS DISEASES;

EID: 84928468984     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.036     Document Type: Review

References (121)

1. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/ progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28:839-847.
2. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007;25:1298-1306.
3. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014;510:235-240.
4. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326:818-823.
5. Cartier N, Hacein-Bey-Abina S, Von Kalle C, et al. [Gene therapy of x-linked adrenoleukodystrophy using hematopoietic stem cells and a lentiviral vector]. Bull Acad Natl Med 2010;194:255-264; discussion 264-268.
6. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158.
7. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott- Aldrich syndrome. Science 2013;341:1233151.
8. Kajaste-Rudnitski A, Pultrone C, Marzetta F, et al. Restriction factors of retroviral replication: the example oftripartite motif (TRIM) protein 5 alpha and 22. Amino Acids 2010;39:1-9.
9. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol 2012;13:214-222.
10. Towers GJ, Noursadeghi M. Interactions between HIV-1 and the cell-autonomous innate immune system. Cell Host Microbe 2014;16:10-18.
11. Bieniasz PD. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 2004;5:1109-1115.
12. Strebel K, Luban J, Jeang KT. Human cellular restriction factors that target HIV-1 replication. BMC Med 2009; 7:48.
13. King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol 2011;11:685-692.
14. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
15. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NFkappaB by Toll-like receptor 3. Nature 2001;413:732-738.
16. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531.
17. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-1529.
18. Lund J, Sato A, Akira S, et al. Toll-like receptor 9- mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003;198:513-520.
19. Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004;10:1366-1373.
20. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-820.
21. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101-105.
22. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004;5:730-737.
23. Ablasser A, Bauernfeind F, Hartmann G, et al. RIG-Idependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 2009;10:1065-1072.
24. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009;138:576-591.
25. Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007;448:501-505.
26. Iwasaki A. Innate immune recognition of HIV-1. Immunity 2012;37:389-398.
27. Mogensen TH, Melchjorsen J, Larsen CS, Paludan SR. Innate immune recognition and activation during HIV infection. Retrovirology 2010;7:54.
28. Mitchell R, Chiang CY, Berry C, Bushman F. Global analysis of cellular transcription following infection with an HIV-based vector. Mol Ther 2003;8:674-687.
29. Breckpot K, Escors D, Arce F, et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 2010;84:5627-5636.
30. Rossetti M, Gregori S, Hauben E, et al. HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. Hum Gene Ther 2011;22:177-188.
31. Agudo J, Ruzo A, Kitur K, et al. A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade. Mol Ther 2012;20:2257-2267.
32. Sutlu T, Nystrom S, Gilljam M, et al. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum Gene Ther 2012;23: 1090-1100.
33. Moore MD, Hu WS. HIV-1 RNA dimerization: it takes two to tango. AIDS Rev 2009;11:91-102.
34. Freed EO, Martin MA. HIVs and their replication. In: Field's Virology, 5th edition. DM Knipe, PM Howley, eds. (Lippincot, Williams & Wilkins, Philadelphia, PA). 2007; pp. 2107-2186.
35. Berg RK, Melchjorsen J, Rintahaka J, et al. Genomic HIV RNA induces innate immune responses through RIG-Idependent sensing of secondary-structured RNA. PLoS One 2012;7:e29291.
36. Goldfeld AE, Birch-Limberger K, Schooley RT, Walker BD. HIV-1 infection does not induce tumor necrosis factor-alpha or interferon-beta gene transcription. J Acquir Immune Defic Syndr 1991;4:41-47.
37. Yan N, Regalado-Magdos AD, Stiggelbout B, et al. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010;11:1005-1013.
38. Gao D, Wu J, Wu YT, et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 2013;341:903-906.
39. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008;134:587-598.
40. Ablasser A, Hemmerling I, Schmid-Burgk JL, et al. TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J Immunol 2014;192:5993-5997.
41. Mankan AK, Schmidt T, Chauhan D, et al. Cytosolic RNA:DNA hybrids activate the cGAS-STING axis. EMBO J 2014;33:2937-2946.
42. Wahba L, Amon JD, Koshland D, Vuica-Ross M. RNase H and multiple RNA biogenesis factors cooperate to prevent RNA:DNA hybrids from generating genome instability. Mol Cell 2011;44:978-988.
43. Gunther C, Kind B, Reijns MA, et al. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest 2015;125:413-424.
44. Monroe KM, Yang Z, Johnson JR, et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 2014;343:428-432.
45. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014;505:509-514.
46. Merten OW, Charrier S, Laroudie N, et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 2011;22:343-356.
47. Hilditch L, Towers GJ. A model for cofactor use during HIV-1 reverse transcription and nuclear entry. Curr Opin Virol 2014;4C:32-36.
48. Lahaye X, Satoh T, Gentili M, et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNAby the innate sensor cGAS in dendritic cells. Immunity 2013;39:1132-1142.
49. Rasaiyaah J, Tan CP, Fletcher AJ, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 2013;503:402-405.
50. Pertel T, Hausmann S, Morger D, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011;472:361-365.
51. Grutter MG, Luban J. TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. Curr Opin Virol 2012;2:142-150.
52. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004;427:848-853.
53. Evans ME, Kumkhaek C, Hsieh MM, et al. TRIM5alpha variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34 cells in vitro and in vivo. Mol Ther 2013;22:348-358.
54. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
55. Schwefel D, Groom HC, Boucherit VC, et al. Structural basis of lentiviral subversion of a cellular protein degradation pathway. Nature 2014;505:234-238.
56. Laguette N, Bregnard C,Hue P, et al. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 2014;156:134-145.
57. Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006;24:801-812.
58. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904-908.
59. Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol 2011;186:5367-5375.
60. Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood 2012;119:2991-3002.
61. Sioud M, Floisand Y, Forfang L, Lund-Johansen F. Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34 + progenitor cells along the myeloid lineage. J Mol Biol 2006;364:945-954.
62. Guo YM, Ishii K, Hirokawa M, et al. CpG-ODN 2006 and human parvovirus B19 genome consensus sequences selectively inhibit growth and development of erythroid progenitor cells. Blood 2010;115:4569-4579.
63. Liu J, Guo YM, Hirokawa M, et al. A synthetic doublestranded RNA, poly I:C, induces a rapid apoptosis of human CD34( + ) cells. Exp Hematol 2012;40:330-341.
64. De Luca K, Frances-Duvert V, Asensio MJ, et al. The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate. Leukemia 2009;23:2063-2074.
65. Yanez A, Megias J, O'Connor JE, et al. Candida albicans induces selective development of macrophages and monocyte derived dendritic cells by a TLR2 dependent signalling. PLoS One 2011;6:e24761.
66. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002;418:646-650.
67. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008;451:425-430.
68. Van Damme N, Goff D, Katsura C, et al. The interferoninduced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008;3:245-252.
69. Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011;474:658-661.
70. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011;474:654-657.
71. Goujon C, Moncorge O, Bauby H, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013;502:559-562.
72. Kane M, Yadav SS, Bitzegeio J, et al. MX2 is an interferon- induced inhibitor of HIV-1 infection. Nature 2013;502:563-566.
73. Liu Z, Pan Q, Ding S, et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 2013;14:398-410.
74. Kahl CA, Cannon PM, Oldenburg J, et al. Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIVderived lentiviral vectors. Gene Ther 2008;15:1079-1089.
75. Baldauf HM, Pan X, Erikson E, et al. SAMHD1 restricts HIV-1 infection in resting CD4( + ) T cells. Nat Med 2012;18:1682-1687.
76. Goldstone DC, Ennis-Adeniran V, Hedden JJ, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011;480:379-382.
77. Lahouassa H, Daddacha W, Hofmann H, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012;13:223-228.
78. Sokolskaja E, Berthoux L, Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol 2006;80:2855-2862.
79. Towers GJ. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007;4:40.
80. Petrillo C, Cesana D, Piras F, et al. Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells. Mol Ther 2015;23:352-362.
81. Busnadiego I, Kane M, Rihn SJ, et al. Host and viral determinants of mx2 antiretroviral activity. J Virol 2014; 88:7738-7752.
82. Goujon C, Malim MH. Characterization of the alpha interferon- induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol 2010; 84:9254-9266.
83. Allouch A, Di Primio C, Alpi E, et al. The TRIM family protein KAP1 inhibits HIV-1 integration. Cell HostMicrobe 2011;9:484-495.
84. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007;117:473-481.
85. Wolf D, Goff SP. TRIM28 mediates primer binding sitetargeted silencing of murine leukemia virus in embryonic cells. Cell 2007;131:46-57.
86. Rowe HM, Jakobsson J, Mesnard D, et al. KAP1 controls endogenous retroviruses in embryonic stem cells. Nature 2010;463:237-240.
87. Allouch A, David A, Amie SM, et al. p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci USA 2013;110: E3997-E4006.
88. Pauls E, Ruiz A, Riveira-Munoz E, et al. p21 regulates the HIV-1 restriction factor SAMHD1. Proc Natl Acad Sci USA 2014;111:E1322-E1324.
89. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007;7:610-621.
90. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells. Nat Med 1996;2:52-58.
91. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-489.
92. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32: 593-604.
93. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-737.
94. Mantovani A, Biswas SK, Galdiero MR, et al. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013;229:176-185.
95. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009;9:259-270.
96. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-286.
97. Bobadilla S, Sunseri N, Landau NR. Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. Gene Ther 2012.
98. Durand S, Cimarelli A. The inside out of lentiviral vectors. Viruses 2011;3:132-159.
99. Tareen SU, Kelley-Clarke B, Nicolai CJ, et al. Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells. Mol Ther 2013;22:575-587.
100. Berger G, Durand S, Goujon C, et al. A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc 2011;6:806-816.
101. Sharova N, Wu Y, Zhu X, et al. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathogens 2008;4:e1000057.
102. EscobarG,Moi D, RanghettiA, et al. Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. Sci Transl Med 2014;6:217ra213.
103. Chiriaco M, Farinelli G, Capo V, et al. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. Mol Ther 2014;22:1472-1483.
104. Rehwinkel J, Maelfait J, Bridgeman A, et al. SAMHD1- dependent retroviral control and escape in mice. EMBO J 2013;11;32:2454-2462.
105. Lahouassa H, Daddacha W, Hofmann H, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012;12;13:223-228.
106. Manel N, Hogstad B, Wang Y, et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010;467:214-217.
107. Santoni de Sio FR, Gritti A, Cascio P, et al. Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells. Stem Cells 2008; 26:2142-2152.
108. Uchida N, Hsieh MM, Washington KN, Tisdale JF. Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid. Exp Hematol 2013;41:779-788.e771.
109. Santoni de Sio FR, Cascio P, Zingale A, et al. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 2006;107:4257-4265.
110. Wang CX, Sather BD, Wang X, et al. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 2014;124:913-923.
111. Li, L, Torres-Coronado M, Gu A, et al. Enhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin. Stem Cells Trans Med 2014;3:1199-1208.
112. Naldini L. Ex vivo gene transfer and correction for cellbased therapies. Nat Rev Genet 2011;12:301-315.
113. Amirache F, Levy C, Costa C, et al. Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood 2014;123:1422-1424.
114. Finkelshtein D, Werman A, Novick D, et al. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci USA 2013; 110:7306-7311.
115. Girard-Gagnepain A, Amirache F, Costa C, et al. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood 2014;124:1221-1231.
116. Humbert JM, Frecha C, Amirache Bouafia F, et al. Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cells. J Virol 2012;86:5192-5203.
117. Brendel C, Goebel B, Daniela A, et al. CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells. Mol Ther 2015;23:63-70.
118. Kays SK, Kaufmann KB, Abel T, et al. CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells. Stem Cells Dev 2015;24:714-723.
119. Scaramuzza S, Biasco L, Ripamonti A, et al. Preclinical safety and efficacy of human CD34( + ) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol Ther 2013;21:175-184.
120. Sellers SE, Dumitriu B, Morgan MJ, et al. No impact of lentiviral transduction on hematopoietic stem/progenitor cell telomere length or gene expression in the rhesus macaque model. Mol Ther 2014;22:52-58.
121. Tsang J, Chain BM, Miller RF, et al. HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation. Aids 2009;23:2255-2263.